Immunic, Inc. short interest in 2022
In 2022, Immunic, Inc.'s disclosed short interest ran from 4.47% of shares outstanding on 14 Jan 2022 to 18.01% on 30 Dec 2022, a change of +13.54 percentage points. The year's high was 18.31% on 15 Dec 2022 and its low 2.31% on 30 Sep 2022, averaging 7.35% across 23 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 11.25 days on 15 Dec 2022. Full history: Immunic, Inc..
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2022 in figures
- Start of year
- 4.47% (14 Jan 2022)
- End of year
- 18.01% (30 Dec 2022)
- Change
- +13.54 pp
- High
- 18.31% (15 Dec 2022)
- Low
- 2.31% (30 Sep 2022)
- Average
- 7.35%
- Highest days to cover
- 11.25 (15 Dec 2022)
- SEC filings marked
- 8
Every report in 2022
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 14 Jan 2022 | 4.47% | 2.32 | |
| 31 Jan 2022 | 4.74% | 6.00 | |
| 15 Feb 2022 | 5.39% | 3.65 | |
| 28 Feb 2022 | 5.14% | 5.12 | 10-K filed, results (8-K) |
| 15 Mar 2022 | 6.04% | 6.35 | |
| 31 Mar 2022 | 5.74% | 11.12 | |
| 14 Apr 2022 | 5.43% | 9.45 | |
| 29 Apr 2022 | 4.35% | 3.42 | |
| 13 May 2022 | 4.06% | 3.69 | 10-Q filed, results (8-K) |
| 31 May 2022 | 5.09% | 4.92 | |
| 15 Jun 2022 | 6.21% | 1.00 | |
| 30 Jun 2022 | 3.67% | 2.02 | |
| 15 Jul 2022 | 3.79% | 9.17 | |
| 29 Jul 2022 | 3.45% | 10.11 | |
| 15 Aug 2022 | 3.18% | 5.11 | 10-Q filed, results (8-K) |
| 31 Aug 2022 | 3.01% | 10.84 | |
| 15 Sep 2022 | 2.92% | 10.79 | |
| 30 Sep 2022 | 2.31% | 3.82 | |
| 31 Oct 2022 | 17.97% | 1.10 | |
| 15 Nov 2022 | 17.81% | 3.77 | 10-Q filed, results (8-K) |
| 30 Nov 2022 | 17.94% | 6.13 | |
| 15 Dec 2022 | 18.31% | 11.25 | |
| 30 Dec 2022 | 18.01% | 8.74 |
See also: Immunic, Inc.'s full history · most shorted US stocks of 2022 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.